Literature DB >> 31493900

Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study.

Gry Johansen1, Pernilla Dahm-Kähler2, Christian Staf3, Angelique Flöter Rådestad4, Kenny A Rodriguez-Wallberg5.   

Abstract

OBJECTIVE: To compare the oncologic outcome of women who underwent fertility-sparing surgery (FSS) vs. radical surgery (RS) for treatment of NEOC in a prospective, nationwide, population-based study and report on the reproductive outcomes in women after FSS.
METHODS: Using the Swedish Quality Register for Gynecological Cancer, we identified all women ages 18-40 treated with either FSS or RS for stage I NEOC between 2008 and 2015. Progression-free survival (PFS) and overall survival (OS) rates were compared using the Kaplan-Meier method. Data on use of assisted reproductive technology (ART) treatments and obstetrical outcomes after FSS were extracted from the National Quality Register for Assisted Reproduction (Q-IVF) and the Swedish Medical Birth Register.
RESULTS: During the study period, 73 women ages 18-40 received a stage I NEOC diagnosis. The majority, 78% (n = 57), underwent FSS. The 5-year OS rate, regardless of surgical approach, was 98%. There were no statistical differences between OS and PFS rates in women treated with FSS, compared to RS. Recurrences were more common after RS than FSS: 12.5% (2/16) vs. 3.5% (2/57), respectively. Following FSS, 11 women gave birth to 13 healthy children (all conceived naturally). Additionally, 12% of the women in the cohort developed infertility and received ART treatment (n = 7).
CONCLUSION: FSS is not associated with worse oncologic outcomes than RS in young women with early stage NEOC. The prognosis was excellent in both groups, with an OS of 98%. Natural fertility was maintained in women treated with FSS, only 12% required ART treatment.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assisted reproductive technology treatment; Conception-rate; Early-stage non-epithelial ovarian cancer; Fertility-sparing surgery; Live birth; Obstetrical outcome; Overall survival; Progression-free survival

Mesh:

Year:  2019        PMID: 31493900     DOI: 10.1016/j.ygyno.2019.08.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

Review 1.  Oncological Prognosis and Fertility Outcomes of Different Surgical Extents for Malignant Ovarian Sex-Cord Stromal Tumors: A Narrative Review.

Authors:  Jiawei Li; Jun Li; Wei Jiang
Journal:  Cancer Manag Res       Date:  2022-02-18       Impact factor: 3.989

2.  A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women.

Authors:  Gry Johansen; Pernilla Dahm-Kähler; Christian Staf; Angelique Flöter Rådestad; Kenny A Rodriguez-Wallberg
Journal:  BMC Cancer       Date:  2020-10-19       Impact factor: 4.430

Review 3.  Non-Epithelial Ovarian Cancers: How Much Do We Really Know?

Authors:  Alison Cheung; Sidrah Shah; Jack Parker; Pavandeep Soor; Anu Limbu; Matin Sheriff; Stergios Boussios
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

Review 4.  Fertility-Sparing Treatment for Early-Stage Cervical, Ovarian, and Endometrial Malignancies.

Authors:  Roni Nitecki; Terri Woodard; J Alejandro Rauh-Hain
Journal:  Obstet Gynecol       Date:  2020-12       Impact factor: 7.623

Review 5.  Gynecological cancer among adolescents and young adults (AYA).

Authors:  Silvia Triarico; Michele Antonio Capozza; Stefano Mastrangelo; Giorgio Attinà; Palma Maurizi; Antonio Ruggiero
Journal:  Ann Transl Med       Date:  2020-03

6.  Germinal ovarian tumors in reproductive age women: Fertility-sparing and outcome.

Authors:  Miriam Dellino; Erica Silvestris; Vera Loizzi; Angelo Paradiso; Rosalia Loiacono; Carla Minoia; Antonella Daniele; Gennaro Cormio
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.